Outpatient therapeutic chronic opioid consumption in Italy: a one-year survey. by Miceli, L. et al.
Vol. 83 - No. 1 MiNerVa aNestesiologica 33
analysis of opioid consumption is particu-
larly important, since opioids are key medica-
tions for the treatment of moderate to severe 
pain, and some of them are listed by the World 
Health organizations as essential drugs.3
in italy despite the availability of many data 
regarding total opioid prescriptions, a database 
including all patients on chronic opioid thera-
py still does not exist.
in other words, we can identify the total 
prescribed opioid amount but we do not know 
in italy since the 38/2010 law regarding Pal-liative care and pain therapy has been pro-
mulgated, the prescription of opioid drugs was 
increasing.1 the same trend was documented 
worldwide.2 therefore, analysis of national 
analgesic consumption can provide useful in-
formation about pain medication use trends 
and might enable us to better understand be-
havior associated with drug prescription.
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a B s t r a c t
BacKgroUND: in italy since the 38/2010 law concerning Palliative care and pain therapy has been promulgated, the 
consumption of opioids started increasing. However, despite the availability of a large amount of data regarding opioid 
prescription, a database including all patients on chronic opioid therapy does not yet exist.
MetHoDs: retrospective analysis of analgesic opioid consumption was performed between January 2013 and Decem-
ber 2013 using the data of national refunded medications for outpatients, collected by italian Ministry of Health. We 
considered patients on chronic opioid therapy those patients with at least three opioids prescriptions in three consecutive 
months and/or six opioid prescriptions in six even not consecutive months in the observation period. We considered 
cancer patients those with neoplasm exemption code in the scheduled prescription and/or patients with at least one roos 
prescription (rapid onset opioids, approved in italy for Break through cancer Pain-BtcP- only). We also calculated the 
patient’s morphine daily mean dose (MED) converting all prescribed opioids in equivalent of morphine using specific 
conversion tables.
resUlts: this census revealed a total of 422,542 patients in chronic therapy with opioids, of those 369.961 with 
chronic non-cancer pain and 52,581 with chronic cancer pain. this represents about 4% of the estimated requirement in 
italy for both groups based on previous surveys regarding the prevalence of chronic pain.
coNclUsioNs: relatively to MeD, We found that in italy chronic cancer pain patients receive doses similar to patients 
with cancer pain in other literature reports, whereas patients with chronic non-cancer pain received lower dosages.
(Cite this article as: Miceli l, Bednarova r, Di cesare M, santori e, spizzichino M, Di Minco l, et al. outpatient therapeutic chron-
ic opioid consumption in italy: a one-year survey. Minerva anestesiol 2017;83:33-40. Doi: 10.23736/s0375-9393.16.11099-5)
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We defined “a chronic opioid user” a pa-
tients that, within the twelve months of sur-
vey, received at least 3 opioids prescriptions 
in three consecutive months (according to the 
international association for the study of Pain 
– IASP – definition of chronic pain)5 and/or six 
opioid prescriptions in six months within the 
twelve months of survey, even in non-consec-
utive months.
We first divided the patients in three groups: 
total patients (who received at least one opi-
oid prescription in the 2013), cancer patients 
and non cancer patients, identifying cancer pa-
tients those having the neoplasm italian ticket 
exemption code in the single prescription and/
or those that received in 2013 year at least one 
breakthrough cancer pain (BtcP) drug pre-
scription, approved in italy exclusively for 
cancer pain (fentanyl citrate, fentanyl buccal 
tablets, fentanyl sublingual tablets, fentanyl 
nasal spray).
We also analyzed the monthly chronic pa-
tients distribution (from three to twelve months 
according to chronic opioid user definition de-
scribed above).
subsequently all opioid prescribed for each 
patient were converted using specific conver-
sion tables 6, 7 in MeD (morphine equivalent 
dosage) and them analyzed.8
Statistical analysis
Data are presented as absolute values, per-
centage or mean±standard deviation (sD); the 
mean dose of MeD are represented as a value 
and IC 95 (interval of confidence 95%). Sex 
differences in opioid prescriptions and pre-
scription trends in all patients, cancer and non-
cancer ones, were analyzed with two-tailed 
student t test for unpaired samples.
Results
a total of 2,520,382 patients had at least 
one opioid prescription between January 2013 
and December 2013 (table i), 422,542 (preva-
lence on total italian population 0.7%) were 
patients on chronic opioid therapy (16.75% 
of total opioid prescription-receiving patients 
how many patients are using those drugs, and 
in which proportion opioids are distributed 
among them.
We also do not know the mean opioid dose 
(MeD) prescribed to patients on chronic thera-
py with these drugs.
identifying appropriateness related to ade-
quacy in terms of amounts and trends of opioid 
consumption provides precious data for evalu-
ating policy and economic changes.4
the aim of the study was to describe the pre-
scription patterns in patients on chronic opioid 
therapy in term of number of chronic patients 
and opioid dosage prescribed. Data, based on 
register of outpatients refunded prescriptions 
obtained from italian Ministry of Health, are 
registered between January 2013 and Decem-
ber 2013.
Materials and methods
retrospective analysis of analgesic prescrip-
tions was carried out between January 2013 
and December 2013 using data of national re-
funded medications for outpatients, furnished 
by Italian Ministry of Health (Office number 
iii, Head Quarter Health Planning). according 
to the ATC classification (Anatomical, Thera-
peutic, chemical) system data was collected 
from N02a group (central analgesics), with 
exception of acetaminophen alone. Parenteral 
formulations and in-hospital prescribed drugs 
were excluded from the collected data.
Drugs records included the following sub-
stances, alone or in combination: morphine 
(except intravenous formulations), oxycodone, 
hydromorphone, codeine, tramadol, fentanyl 
(except intravenous formulations), tapentadol, 
and buprenorphine except sublingual formula-
tions.
Data from the included prescriptions were: 
anonymous patient personal identification 
code, region of residence, ticket exemption 
code (if present), sex, age, atc prescribed, 
date of prescription, dose of the prescribed 
drug and number of packages prescribed.
Patient’s age was presented divided in mul-
tiple groups of five year each (for example 50-
54 years, 55-59 years).
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those patients dividing them in cancer and non 
cancer subgroups: cancer patients have a mi-
nor mean age and do not present significant 
sex difference (Figure 2), non-cancer patients 
on the other hand are mainly elderly females 
(Figure 3).
the two tailed t student test for unpaired 
samples showed a P<0.05 in sex distribu-
tion for all age clusters from 50-54 in overall 
chronic patients and in non-cancer patients 
(Figures 1, 3).
total opioid prescriptions (table ii) dur-
ing the observation period in italy has been 
in 2013). We then divided chronic patients in 
two groups: cancer patients (according to the 
above mentioned criteria) reaching 52,581 pa-
tients (2.08% of total opioid users, prevalence 
on total italian population 0.08%) and non-
cancer patients 369,961 (representing 14.67% 
of total patients on opioid therapy, prevalence 
on total italian population 0.62%).
a demographic description of sex and age 
distribution (Figure 1) in chronic patients 
shows that most of the patients are over 65 
years old, mainly females for each age class.
such distribution differs when we analyze 
Table I.—Chronic pain patients distribution: total (in bold) and monthly of opioid use; data divided also in chronic 
oncological and chronic non oncological patients.
Months of 





1 1,513,049 0 58,505 0 1,454,544 0
2 378,333 0 26,271 0 352,062 0
3 175,110 53,667 16,351 8806 158,759 44,861
4 105,826 49,485 11,293 7860 94,533 41,625
5 74,682 46,008 8380 6854 66,302 39,154
6 58,242 58,242 6393 6393 51,849 51,849
7 46,938 46,938 5127 5127 41,811 41,811
8 39,714 39,714 4169 4169 35,545 35,545
9 35,108 35,108 3502 3502 31,606 31,606
10 31,256 31,256 3109 3109 28,147 28,147
11 29,642 29,642 2977 2977 26,665 26,665
12 32,482 32,482 3784 3784 28,698 28,698
total 2,520,382 422,542 149,861 52,581 2,370,521 369,961
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Figure 2.—age and sex distribution in chronic neoplasm opioid users. X axys: age groups (years); Y axys: number of patients.
Figure 3.—age and sex distribution in chronic non oncological opioid users. X axys: age groups (years); Y axys: number of 
patients.
9,323,790, of those 5,622,172 were for chron-
ic users (60.3%), and the remaining 3,701,618 
(39.7%) for non-chronic patients.
the seven most prescribed opioids in gener-
al population were the following (in descend-
ing order): weak opioids (codeine 35.2% and 
tramadol 21.5%), oxycodone 18.6%, fentanyl 
11.1%, tapentadol 6.1%, morphine 2.4%.
in chronic patients however codeine was 
less prescribed (27.3%) in favor primarily of 
oxycodone (21.5%) and fentanyl (15.2%).
the mean number of annual opioid pre-
scription per patient was 3.7+2.5; the non-
chronic patients had a mean of 1.8±0.9 annual 
prescriptions, chronic patients 13.3±8.1 pre-
scription per year, with a mean of 20.6±14.5 
prescriptions in chronic cancer patients.
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to calculate, because the roos (rapid onset 
opioids) formulation of fentanyl, don’t have a 
defined conversion value.
We add a flowchart to describe the classifi-
cation of total opioid patient users in chronic 
opioid users and acute opioid users for pre-
sumed cancer and non-cancer pain and the dis-
tribution of those prescriptions (Figure 4).
Discussion
Presented data show (table i) that between 
January 2013 and December 2013 the num-
ber of chronic prescriptions of opioids in italy 
was 422,542 (prevalence of 0.7%, divided in 
chronic non cancer pain 0.62% and chronic 
cancer pain 0.08%) compared to 2,520,382 
non-chronic opioid prescription. the chronic 
use of opioid painkillers in italy hence is still 
dose (expressed in MeD) in chronic patients, 
in both, cancer and non-cancer subgroups 
(table iii): as a results the mean dose in non-
cancer patients was (table iii) 30.13 mg/mor-
phine/daily compared to 79.47 mg/morphine/
daily in chronic cancer patients (student’s t-
test P<0.001). in 1656 prescriptions for cancer 
patients and in 18,197 prescriptions for non-
cancer patients the MeD it was not possible 
Figure 4.—Flowchart to describe the classifications of total 
opioid user patients in chronic and acute opioid users and in 
cancer and non-cancer pain.
Table II.—Opioids prescribed in Italian patients, total and divided in chronic and non-chronic users.
atc code total patients chronic patients Non-chronic patients
N02aa59 – codein 3,279,702 1,535,361 1,744,341
N02aX02 – tramadol 2,006,886 1,204,805 802,081
N02aa05 – oxycodon and oxycodon+ naloxon 1,085,582 757,439 328,143
N02aB03 – Fentanyl 1,038,030 856,347 181,683
 – transdermal 797,366 648,718 148,648
 – other (roos-rapid onset opioids for BtcP) 240,664 207,629 33,035
N02aa55 – oxycodone+ acetaminophen 654,366 449,646 204,720
N02aX06 - tapentadol 568,329 326,995 241,334
N02aa01 – Morphine 228,090 168,991 59,099
 – syrup 89,513 64,811 24,702
 – others 138,577 104,180 34,397
N02aX52 - tramadol, associations 183,093 100,516 82,577
N02ae01 - Buprenorphin 169,150 136,103 33,047
N02aa03 - idromorfon 103,085 83,901 19,184
N02Be51 – acetaminophen, others associations 7153 1810 5343
N02ag01 - Morphine and antispasmodic 274 256 18
r05Da04 – codein 38 2 36
N07Bc51 - Buprenorphin, associations 12 0 12
totale 9,323,790 5,622,172 3,701,618
atc: anatomical therapeutic chemical.
Table III.—Mean daily morphine equivalent dose (MED) in chronic cancer and non-cancer patients.
chronic patients Number
Morphine equivalent dose (MeD) (mg)
Mean daily MeD ic 95%
Neoplasm* 50,925 79.47 ic95% 78.51-80.43
No neoplasm** 351,764 30.13 ic95% 29.99-30.27
IC: interval of confidence.
*in 1656 patients it has not been possible to measure the MeD.
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patients in terms of use of public resources (a 
small number of patients-about 422,000 com-
pared to 2,500,000 of total patients-recruit 
the greatest part of the prescriptions – about 
5.600.000 compared to over 9,200,000 total 
prescriptions).
in patients on chronic opioid therapy among 
strong opioids oxycodone alone or associated 
with naloxone is the mostly prescribed drug 
when non-cancer patients are considered.
Figures 1-3 shows that patients with chronic 
opioid therapy are elderly, with female pre-
dominance, a fact that might be explained by 
the prevalence of females in italian population 
and furthermore is in accordance with other 
literature data.13-15
this fact in our opinion can be also ex-
plained by a cultural and socioeconomic phe-
nomena where younger males, often affected 
by chronic pain, mostly benign, as already ex-
plained by Breivik et al.,12 missed the attention 
of pain therapist.
table iii is fundamental to answer the ques-
tion about the mean daily dose of opioid ther-
apy: some data in literature 15 showed a mean 
posology of about 86 morphine equivalent 
dose (MeD) in cancer patients, being similar 
to data obtained in our study, and about 62 
MeD in non cancer patients treated with opi-
oids for 6-12 months, being twice the MeD 
revealed by our observation.
in cepeda’s work 15 collected data from 
48.986 patients in a 8 years period (2002-2008) 
in Us, with a mean age of 44.5 years, similar 
to our results, and a prevalence of female sex, 
also similar to our findings. Moreover some 
differences in the age group might be related 
to the fact that in the Us study data were col-
lected from an insurance database in which pa-
tients over 65 years, low income patients and 
people not able to work are often excluded, 
whereas italian data include all refunded pre-
scriptions in the 2013 with no restrictions.
others Us studies 16, 17 showed lower MeD 
prescriptions respect to cepeda’s data, at least 
in particular subset patients (veterans). ed-
lund 16 and Macey 17 registered respectively 
a median MeD of 21 mg/die — range 10-997 
mg/die — (in the years 2009-2011) and av-
an exception rather than a rule, despite various 
warnings, hidden and explicit campaigns that 
aim to emphasize elevated chronic use and an 
abuse potential coming from Usa.9 More than 
80% of the chronic users suffer non-cancer 
pain, a fact that might sign of a cultural change 
in physician behavior, probably promoted 
by italian law 38/2010 10 that encourages- at 
least in initial phase of pain management- and 
simplifies opioid prescription for moderate to 
severe pain independently of its origin. this 
trend emerges despite the widespread opio-
phobia that still relegates italy to the bottom of 
opioid consumers list in europe.11
the prevalence of patients with chronic 
non cancer pain (with moderate to severe in-
tensity) in italy is approximately 20% namely 
(12,000,000 residents),12 of those 422,000 
during the observation period were receiving 
prescriptions for their health problem with an 
appropriate drug (at least until a target oriented 
care for pain relief was available), representing 
about 4% of potential candidates, in consider-
ation that italian population is approximately 
60,000,000 citizens (National institute of sta-
tistics).13
in patients with cancer having a prevalence 
of about 3.5% (National institute of statis-
tics-13), 60% are estimated to face mild to se-
vere pain 14 and 53.000 patients are on chronic 
opioid treatment, being again about 4% only 
of potential candidates (estimated 1.3 million 
people).
this means that 96% of chronic pain pa-
tients, both of cancer and non-cancer origin, 
can unlikely have access to appropriate pain 
therapy at least until the correct diagnosis and 
specific treatment are performed.
table ii shows that all patients including 
chronic and the non chronic opioid users were 
treated in 50% of cases with weak opioids, 
whereas in chronic opioid users strong opioids 
predominate on weak opioids; this fact could 
be due to the pain being more severe when 
chronic compared to the probably less severe 
acute pain. the tables i, ii highlight that 17% 
of the patients taking opioids in 2013 received 
60% of the total prescriptions. this data un-
derline the numeric importance of chronic pain 
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Conclusions
We performed a patient-based (number of 
users) analysis of the prescribing behavior in 
italy during the 2013-year rather than num-
ber of opioid packages prescribed in the same 
period. this has led to a census of more than 
422.000 patients on chronic therapy with opi-
oids (about 50.000 cancer patients and 370.000 
non cancer patients), representing nevertheless 
only 4% of the estimated pain therapy appli-
cants.
relatively to morphine daily dose our data 
(79.4 MeD in cancer patients and 30.1 MeD 
in non cancer patients) showed that in italy 
cancer patients received adequate opioid dos-
es, whereas the non cancer patients received 
minor opioid.
Key messages
 — The study used a “number of 
patients”-centered data base of chronic 
opioids users instead of “number of drug-
pack”-centered data base, already known 
in literature.
 — this database collected all 2013 opi-
oids prescription in italy (about 9 million 
of records) provided by italian Ministry of 
Health.
 — the study analyzed and compared 
with other countries the mean MeD (mor-
phine equivalent dose) of opioids in the 
scheduled opioids chronic users.
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s
(ei
the
r s
po
rad
ica
lly
 o
r s
ys
te
m
at
ica
lly
,
 
e
ith
er
 p
rin
te
d 
or
 e
le
ct
ro
ni
c) 
of 
the
 A
rtic
le
 fo
r 
a
ny
 p
ur
po
se
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 d
ist
rib
u
te
 th
e 
el
ec
tro
ni
c 
co
py
 o
f t
he
 a
rti
cl
e 
th
ro
ug
h 
on
lin
e 
in
te
rn
e
t a
nd
/o
r i
nt
ra
n
e
t f
ile
 s
ha
rin
g 
sy
st
em
s,
 
e
le
ct
ro
ni
c 
m
ai
lin
g 
or
 a
ny
 o
th
er
m
e
a
n
s 
w
hi
ch
 m
ay
 a
llo
w
 a
cc
e
ss
 to
 th
e 
Ar
tic
le
.
Th
e 
us
e 
of
 a
ll 
or
 a
ny
 p
ar
t o
f t
he
 A
rti
cl
e 
fo
r 
a
ny
 C
om
m
er
cia
l U
se
 is
 n
ot
 p
er
m
itt
ed
.T
he
 c
re
at
io
n 
of
 d
er
iva
tiv
e
 w
o
rk
s 
fro
m
 th
e 
Ar
tic
le
 is
 n
ot
 p
er
m
itt
ed
.T
he
 p
ro
du
ct
io
n 
of
 re
pr
in
ts
 fo
r 
pe
rs
on
al
 o
r c
om
m
er
cia
l u
se
 is
n
o
t p
er
m
itt
ed
.I
t i
s 
no
t p
er
m
itt
ed
 to
 re
m
ov
e,
 
co
ve
r,
 
ov
e
rla
y, 
o
bs
cu
re
,
 
bl
oc
k,
 o
r c
ha
ng
e 
an
y 
co
py
rig
ht
 n
ot
ice
s 
or
 te
rm
s 
o
f u
se
 w
hi
ch
 th
e 
Pu
bl
is
he
r m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 fr
a
m
e
 o
r 
u
se
 fr
a
m
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
a
de
m
ar
k,
 lo
go
,
o
r 
o
th
er
 p
ro
pr
ie
ta
ry
 in
fo
rm
a
tio
n 
of
 th
e 
Pu
bl
is
he
r.
